Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.46 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552764 | 0.92 | RARB (0.47) | ARAURKAKDRAURKB | |
| SCHEMBL3559039 | 0.92 | AR (0.52) | ARAURKAKDRAURKB | |
| SCHEMBL10965567 | 0.90 | WDR5 (0.55) | ARWDR5MAP1LC3BMAP1LC3AAURKA | |
| SCHEMBL3554342 | 0.89 | LMNA (0.51) | SLC16A3POLB | |
| SCHEMBL3558668 | 0.86 | AR (0.46) | ARAURKAKDRAURKB | |
| SCHEMBL27846668 | 0.85 | WDR5 (0.53) | WDR5POLBNR1H4 | |
| SCHEMBL3561334 | 0.84 | SLC16A3 (0.61) | SLC16A3 | |
| SCHEMBL10750392 | 0.82 | PTPN1 (0.47) | ARMAP1LC3BMAP1LC3AAURKAKDR | |
| SCHEMBL3560661 | 0.82 | HPGD (0.53) | SLC16A3BRD4POLB | |
| SCHEMBL3557388 | 0.82 | ALDH1A1 (0.57) | SLC16A3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | AR 3412/4885WDR5 1795/4885MAP1LC3B 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.